Corpus Intelligence IC Memo — BLOOMINGTON REGIONAL REHABILITATION 2026-04-26 12:47 UTC
IC Memo — BLOOMINGTON REGIONAL REHABILITATION
Investment Committee Memorandum | IN | 40 beds | Grade C | EBITDA uplift $750K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BLOOMINGTON REGIONAL REHABILITATION

CCN 153049 | MONROE, IN | 40 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BLOOMINGTON REGIONAL REHABILITATION is a 40-bed rural/critical access in MONROE, IN with $10.1M in net patient revenue and a -28.8% operating margin. The hospital serves a payer mix of 52.4% Medicare, 1.4% Medicaid, and 46.1% commercial.

Thesis: Turnaround. Our ML models identify $750K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -28.8% to -21.4% (+742bps).

Net Revenue HCRIS$10.1M
Current EBITDA COMPUTED$-2.9M
Operating Margin COMPUTED-28.8%
Occupancy HCRIS42.3%
Revenue / Bed COMPUTED$253K
Net-to-Gross HCRIS66.3%
Distress Probability ML55.5%

2. Market Context & Competitive Position

171
IN Hospitals
-1.1%
State Median Margin
90
Comparable Hospitals

IN has 171 Medicare-certified hospitals with a median operating margin of -1.1%. The target's margin of -28.8% places it below the state median. Among 90 size-comparable peers (20-80 beds), the median margin is -2.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (20-80), prioritizing same-state peers. 90 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BLOOMINGTON REGIONAL REHABILIT (Target)IN40$10.1M-28.8%
INDIANA ORTHOPAEDIC HOSPITAL LIN38$196.8M31.2%
LAPORTE HOSPITALIN74$192.4M19.3%
SCHNECK MEDICAL CENTERIN60$184.2M-0.8%
ORTHOPAEDIC HOSPT.AT PARKVIEWIN37$175.7M36.8%
LUTHERAN MUSCULOSKELETAL CENTEIN39$168.9M25.0%
WITHAM MEMORIAL HOSPITALIN50$158.5M-11.6%
FRANCISCAN HEALTH MOORESVILLEIN80$157.3M26.2%
MAJOR HOSPITALIN46$156.9M-9.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $750K (742bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$212K+210bp18mo
Denial Rate Reduction12.0%6.5%$203K+201bp12mo
Cost to Collect4.5%2.5%$202K+200bp12mo
A/R Days Reduction5200.0%3800.0%$123K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+9bp6mo

5. EBITDA Bridge

Net Collection Rate
$212K
Denial Rate Reduction
$203K
Cost to Collect
$202K
A/R Days Reduction
$123K
Clean Claim Rate
$10K
Total EBITDA Uplift$750K
Current EBITDA$-2.9M
+ RCM Uplift+$750K
Pro Forma EBITDA$-2.2M
Current Margin-28.8%
Pro Forma Margin-21.4%
WC Released (1x)$388K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-4.5M$-11.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-4.5M$-14.3M0.00x-100.0%
Bull Case9.0x11.0x$-4.0M$-13.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-4.0M$-15.7M0.00x-100.0%
Bear Case11.0x10.0x$-4.9M$-14.0M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-4.9M$-17.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 55.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 90 hospitals with 20-80 beds
  • Same-state prioritization (n=91)
  • Comp margins: P25=-11.6% / P50=-2.9% / P75=7.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.